繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 免疫系统 >> 新药推荐 >> CYTOTECT INJ(施多特静脉注射剂)

CYTOTECT INJ(施多特静脉注射剂)

2011-11-09 01:49:04  作者:新特药房  来源:中国新特药网天津分站  浏览次数:526  文字大小:【】【】【
简介: 商品名:CYTOTECT BIOTEST 药品名称:人类巨细胞病毒免疫球蛋白/cytomegalovirus immunoglobulin, human 药理作用:本品系从人血浆制备的含有高水平抗巨细胞病毒(CMV)特异性抗体的免疫球蛋白。 适 ...

部份中文施多特处方资料(仅供参考)
商品名:CYTOTECT BIOTEST
药品名称:
人类巨细胞病毒免疫球蛋白/cytomegalovirus immunoglobulin, human
组成:
1毫升溶液含有:100mg蛋白质,其中人免疫球蛋白组成的至少95%含量的抗体对细胞巨化病毒50IU进一步成分:氯化钠,注射用水
药理作用:
本品系从人血浆制备的含有高水平抗巨细胞病毒(CMV)特异性抗体的免疫球蛋白。
适应症:
用于CMV感染的被动免疫,尤其是预防性或治疗性地应用于接受移植的患者。有静注和肌注用制剂,迄今本品在肾、心脏、骨髓及肝脏移植患者中对CMV感染的预防和治疗效果已进行了初步评估,但确切疗效尚在进一步研究评估中。
不良反应:
类同一般免
副作用
包括恶寒、头痛、发烧、呕吐、过敏反应、恶心以及可能偶而会发生轻微的背部疼痛。
用药注意事项
1.请冷藏保存
2.某些严重的药物副作用可能与输注的速度有关,建议输注期间应小心观察病患之各种症状,投与本品后至少需观察20分钟。
Cytotect Biotest
Human immunoglobulin anti- cytomegalovirus (50 I. U. / ml)
Composition:
1ml solution contains: protein 100 mg, of which human immunoglobulin makes up at least 95% Antibody content against cytomegalovirus 50 I.U. Further constituents : Sodium chloride, water for injections.
Indications:
Prophylaxis of clinical manifestations of cytomegalovirus infection in patients subjected to immunosuppressive therapy, particularly in transplant recipients.
Contra-Indications:
Megalotect® is contra-indicated in patients who are intolerant to human immunoglobulin especially in very rare cases of IgA deficiency, when the patient has antibodies against IgA. Pregnancy and lactation : The safety of this medicinal product for use in human pregnancy has not been established in controlled clinical trials and therefore should only be given with caution to pregnant women and breast-feeding mothers. Long lasting clinical experience with immunoglobulins does indicate that no harmful effects on the course of pregnancy, on the foetus and the neonate are to be expected.
Immunoglobulins are excreted into the milk and may contribute to the transfer of protective antibodies to the neonate.
Special precautions for use: Certain severe adverse drug reactions may be related to the rate of infusion. The recommended infusion rate given under "Method of administration" must be closely followed and patients must be closely monitored and carefully observed for any symptoms throughout the infusion period. Patients should be observed for at least 20 minutes after administration. Effects on ability to drive and use machines: There are no indications that Megalotect® may impair the ability to drive and use machines.
Dosage instructions and duration of application: As a rule doses containing 50 units (PEI) Per Kg Body Weight, Which Corresponds To 1 ml, should be administered. Administration should be initiated on the day of transplantation or the day prior to this (bone marrow transplantation). A total of at least 6 doses at 2 to 3 weeks' intervals should be given.
Interactions with other medicinal products: Live attenuated virus vaccines: immunoglobulin administration may impair for a period of at least 6 weeks and up to 3 months the efficacy of live attenuated virus vaccines such as measles, rubella, mumps, and varicella. After injection of immunoglobulins the transitory rise of the various passively transferred antibodies in the patient's blood may result in misleading positive results in serological testing.
Method of administration: Megalotect® is intended for intravenous use. During the infusion, the rate of 20 drops per minute (corresponding to 1 ml per minute) must not be exceeded. Megalotect® should be inspected visually for particulate matter and discoloration prior to administration. Do not use solutions which are cloudy or which have deposits. Megalotect® should be brought to room or body temperature before administration.
Special precautions for storage: Megalotect® has to be stored at + 2 ºC TO +8 ºC Protected From Light. Do not freeze. Megalotect® should not be used after the expiry date indicated on the label. Any unused solution must be discarded because of bacterial contamination risk.
Presentations:
Ampoules with 5 ml, 10 ml and 20 ml, infusion bottle with 50 ml. For additional information see package insert.
---------------------------------------------------------------
产地国家:德国
原产地英文商品名:
CYTOTECT 2500IU/50ML/VIAL
原产地英文药品名:
HUMAN CYTOMEGALOVIRUS IMMUNOGLOBULIN
中文参考商品译名:
施多特 2500单位/50毫升/瓶
中文参考药品译名:
人类巨细胞病毒免疫球蛋白
生产厂家中文参考译名:
Biotest Italia
生产厂家英文名:
Biotest Italia
---------------------------------------------------------------
产地国家:德国
原产地英文商品名:
CYTOTECT 1000IU/20ML/VIAL
原产地英文药品名:
HUMAN CYTOMEGALOVIRUS IMMUNOGLOBULIN
中文参考商品译名:
施多特 1000单位/20毫升/瓶
中文参考药品译名:
人类巨细胞病毒免疫球蛋白
生产厂家中文参考译名:
Biotest Italia
生产厂家英文名:
Biotest Italia
---------------------------------------------------------------
产地国家:德国
原产地英文商品名:
CYTOTECT 500IU/10ML/VIAL
原产地英文药品名:
HUMAN CYTOMEGALOVIRUS IMMUNOGLOBULIN
中文参考商品译名:
施多特 500单位/10毫升/瓶
中文参考药品译名:
人类巨细胞病毒免疫球蛋白
生产厂家中文参考译名:
Biotest Italia
生产厂家英文名:
Biotest Italia

责任编辑:admin


相关文章
COAGADEX Powder Intravenous (Coagulation Factor X[Human])
ALBUMINAR IV SOLUTION(人血白蛋白输注溶液)
RAPLIXA(Fibrin Sealant(Human))纤维蛋白原[凝血酶]粉末
Medway INJECTION 25%(重组人血清白蛋白注射剂)
美国FDA批准Raplixa用于手术时帮助控制出血
Zetbulin I.V. drip(抗人T淋巴细胞免疫球蛋白静脉滴注)
美国FDA批准Natpara注射液为治疗甲状旁腺功能减退新药
Normosang(hemin,人血晶素注射液)
DRIED HB GLOBULIN for I.M.injection(乙型肝炎免疫球蛋白[冻干粉])
FLEXBUMIN 20% (白蛋白[人]溶液)
Monoclate-P(Antihemophilic Factor VIII (Human))
 

最新文章

更多

· Envarsus(tacrolmus pr...
· Myfortic tablets(麦考...
· ORTHOCLONE OKT3(MUROMO...
· 麦考酚钠缓释片|Myforti...
· CYTOTECT CP(人免疫球蛋...
· Envarsus(tacrolimus pr...
· Zetbulin I.V. drip(抗...
· 依维莫司片|Certican(E...
· 麦考酚酸片|Myfortic(My...
· Neoral(环孢素软胶囊和...

推荐文章

更多

· Envarsus(tacrolmus pr...
· Myfortic tablets(麦考...
· ORTHOCLONE OKT3(MUROMO...
· 麦考酚钠缓释片|Myforti...
· CYTOTECT CP(人免疫球蛋...
· Envarsus(tacrolimus pr...
· Zetbulin I.V. drip(抗...
· 依维莫司片|Certican(E...
· 麦考酚酸片|Myfortic(My...
· Neoral(环孢素软胶囊和...

热点文章

更多

· Envarsus(tacrolmus pr...